Journal of Vascular and Interventional Radiology

Journal of Vascular and Interventional Radiology Journal of Vascular and Interventional Radiology-multidisciplinary publication dedicated to the adva

We’re aware that some users are experiencing difficulty accessing JVIR articles. Our team is actively working to resolve...
03/09/2026

We’re aware that some users are experiencing difficulty accessing JVIR articles. Our team is actively working to resolve the issue as quickly as possible. We appreciate your patience while we work to restore access.

If you need access to a specific article while this issue is being resolved, please contact the JVIR Editorial Office at jvir@sirweb.org for assistance, and we will be happy to help. We apologize for the inconvenience.

SIR has released a new practice guidance document on venous origin chronic pelvic pain in women, now published in JVIR.D...
03/04/2026

SIR has released a new practice guidance document on venous origin chronic pelvic pain in women, now published in JVIR.

Developed by experts from the Women’s Health and Venous Clinical Specialty Councils in collaboration with the SIR Guidelines and Statements Division, this consensus guidance provides recommendations for diagnosis, treatment, complication management, and follow-up care.

Available to read, the document supports evidence-based, consistent care for patients within the broader pelvic venous disorders spectrum.

Read the full guidance in JVIR to learn more: https://brnw.ch/21x0sqh

02/19/2026

🆕 IN : Transarterial Embolization for Refractory Adhesive Capsulitis and Related Tendinopathies: A Systematic Review and Meta-Analysis

Clinical❓: This study aimed to synthesize evidence on transarterial embolization ( ) for adhesive capsulitis and related shoulder tendinopathies to quantify pooled changes in pain, range of motion, functional scores, and safety outcomes.

🕵️Key insight: Transarterial embolization (TAE) produced large, sustained improvements in pain scores, shoulder mobility, and function for refractory adhesive capsulitis. The analysis demonstrated a favorable safety profile with 100% technical success, no severe complications, and a 2.2% moderate adverse event rate.

Why it matters 🤷: This meta-analysis provides a robust evidence base for TAE as a safe and effective minimally invasive treatment option for patients with refractory to conservative management, justifying the progression to randomized trials.

Full 📖: https://brnw.ch/21x05JY

SIR and CIRSE - Cardiovascular and Interventional Radiological Society of Europe have released an updated joint guidelin...
02/18/2026

SIR and CIRSE - Cardiovascular and Interventional Radiological Society of Europe have released an updated joint guideline on occupational protection in interventional radiology, published in JVIR.

The revised guideline addresses new exposure sources, updated evidence, and current best practices for the entire interventional radiology team. Developed by an international panel of experts, it offers clear recommendations supported by an online Annex with additional detail.

Readers can access the guideline by visiting this link: https://brnw.ch/21x03Mr

02/17/2026

🌟NEW IN JVIR🌟: Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model

🕵️: To evaluate the safety and feasibility of treating pancreatic tumors in an Oncopig tumor model, using bumetanide (BU)/ethiodized oil emulsion.

🔑 insight: Intra-arterial injection of bumetanide and ethiodized oil emulsion is safe in treating pancreatic tumors in Oncopigs. No pancreatitis was observed after injection into the pancreatic feeding artery. Tumors decreased in size after 1 week of treatment, with a significant reduction compared with the control group.

Why it matters🤔: This preclinical study demonstrates a safe and feasible intra-arterial approach for targeting pancreatic tumors using an anti-glycolytic emulsion, supporting further investigation into locoregional metabolic therapy for pancreatic cancer.

Full 📰: https://brnw.ch/21x01F5

We are currently working on updates to the JVIR member direct access (SSO implementation). The system is being reinstall...
02/17/2026

We are currently working on updates to the JVIR member direct access (SSO implementation). The system is being reinstalled and may take up to 24 hours to complete. During this time, members may encounter an error page when attempting to access content. A fix is actively in progress.

Need an article or assistance with access in the meantime? Please contact the JVIR Editorial Office at jvir@sirweb.org, and we will be happy to help.

Thank you for your patience as we complete this update.

02/12/2026

NEW IN : Standardized Technique for Prostatic Artery Embolization: A Delphi Consensus Study on Optimized Methods and Emerging Concepts

Clinical❓: To consolidate existing evidence and expert opinion into a structured, stepwise approach for performing ( ) in the management of benign prostatic hyperplasia ( ).

🔑 insight: An international panel of 14 experts achieved high consensus (>80% agreement) on six key procedural steps for PAE, creating a framework to address its technical complexity. Core recommendations include the use of cone-beam CT for procedural planning, embolization to complete stasis from the distal prostatic artery, and mandatory techniques to avoid non-target embolization. The panel also discussed the safety of emerging concepts like liquid embolic agents and the "coil-out" technique.

Why it matters🕵️: This consensus provides interventional radiologists with evidence-based, standardized technical recommendations aimed at optimizing outcomes, improving procedural consistency, and enhancing safety for this effective but technically demanding treatment for benign prostatic hyperplasia.

📰: https://brnw.ch/21wZTjj

**NEW IN JVIR:** Image-Guided Thermal Ablation of Upper Pole Renal Lesions ≤4 cm: Safety and Effectiveness🔍 **Clinical q...
02/09/2026

**NEW IN JVIR:** Image-Guided Thermal Ablation of Upper Pole Renal Lesions ≤4 cm: Safety and Effectiveness

🔍 **Clinical question:**
To compare the safety and effectiveness of image-guided thermal ablation (IGTA) for upper pole versus nonupper pole renal lesions ≤4 cm given the technical challenges of the former.

💡 **Key insight:**
Upper pole renal lesions ≤4 cm treated with image-guided thermal ablation showed comparable adverse event rates to nonupper pole lesions (Grade 3 [severe], 2.4% vs 1.3%, P > .99).

Primary effectiveness was 100% for upper pole lesions versus 97.3% for nonupper pole lesions (P = .54), with no difference in 3-year overall survival (92.9% vs 87.0%, P = .22) and local progression-free survival (90.0% vs 100.0%, P = .17).

Polar location (upper vs nonupper) and R.E.N.A.L./m.R.E.N.A.L. nephrometry scores had no association with adverse events or local progression.

👉 **Why it matters:**
Image-guided thermal ablation for upper pole renal lesions ≤ 4 cm demonstrated safety and oncologic outcomes comparable to non-upper pole lesions despite its increased technical complexity. Polar location alone should not exclude patients from consideration for image-guided thermal ablation.

➡️ **Full article:** https://brnw.ch/21wZN94

**NEW IN JVIR:** Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients wi...
02/06/2026

**NEW IN JVIR:** Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases

🔍 **Clinical Question:**
To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (90Y) transarterial radioembolization (TARE).

💡 **Key insight:**
Overall survival was found to be significantly improved in responders compared with nonresponders among patients with breast cancer liver metastasis treated with yttrium-90 glass microspheres.

Tumor-absorbed dose showed a significant survival advantage above 145 Gy.

No significant difference was found in tumor-absorbed dose between responders and nonresponders.

👉 **Why it matters:**
Metabolic response predicts survival, dose thresholds matter, and higher dose alone does not guarantee response. These results highlight the need for personalized dosimetry in 90Y therapy for breast cancer liver metastases.

📑 **Full article:** https://brnw.ch/21wZJc7

**NEW IN JVIR:** Transarterial Microembolization Therapy for Chronic First Metatarsophalangeal Joint Pain🔍 **Clinical Qu...
01/29/2026

**NEW IN JVIR:** Transarterial Microembolization Therapy for Chronic First Metatarsophalangeal Joint Pain

🔍 **Clinical Question:**
To evaluate the feasibility, safety, and preliminary effectiveness of transarterial microembolization (TAME) for refractory first metatarsophalangeal joint (MTPJ) pain in patients with inflammatory arthritis, gout, or osteoarthritis.

💡 **Key Insight:**
Transarterial microembolization (TAME) targets hypervascularity and pathological nerve ingrowth, key contributors to chronic pain, by selectively embolizing feeder arteries, thereby disrupting pain pathways and reducing inflammatory mediators.

TAME demonstrated significant reduction in pain and weekly analgesic use, establishing it as a safe and effective minimally invasive alternative for managing chronic metatarsophalangeal joint pain refractory to conventional treatments.

👉 **Why it matters:**
The favorable safety profile and effectiveness of TAME suggest potential applications in other small joint pathologies.

➡️ **Full Article:** https://brnw.ch/21wZuWO

01/27/2026

Meet the new Journal of Vascular and Interventional Radiology co-editors-in-chief! Charles E. Ray Jr., MD, PhD, FSIR, and Brian F. Funaki, MD, FSIR, are ready to take on the flagship SIR publication in the new year! jvir.org

**NEW IN JVIR:** Outcomes of Percutaneous Cystic Duct Stent Placement for Acute Cholecystitis❓ **Clinical question:** T...
01/22/2026

**NEW IN JVIR:** Outcomes of Percutaneous Cystic Duct Stent Placement for Acute Cholecystitis

❓ **Clinical question:**
To evaluate whether PCDS placement is safe and effective for nonsurgical patients with acute cholecystitis and cystic duct (CD) anatomy predicts technical success.

💡 **Key insight:**
Percutaneous cystic duct stent (PCDS) placement was attempted in patients with acute cholecystitis who were nonsurgical candidates.
PCDS placement is technically feasible, with 95.3% success in patients with open cystic duct and normal course.

👉 **Why it matters:**
Patients who are diagnosed with acute cholecystitis who are nonsurgical candidates should be offered the option of PCDS placement to avoid the long-term presence of a percutaneous cholecystostomy tube. This can often be achieved in a single procedure after initial percutaneous cholecystostomy tube placement.

➡️ **Full article 🔗:** https://brnw.ch/21wZiRW

Address

1600 John F Kennedy Boulevard
Philadelphia, PA
19103

Telephone

+18006542452

Website

https://www.instagram.com/jvirmedia/, http://www.youtube.com/watch?v=rRBQ9trQ7co, https://twitter.

Alerts

Be the first to know and let us send you an email when Journal of Vascular and Interventional Radiology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram